| Dr David M Coddaire, MD | |
|
609 Washington Hwy, Morrisville, VT 05661-8652 | |
| (802) 888-5639 | |
| (802) 888-6040 |
| Full Name | Dr David M Coddaire |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 52 Years |
| Location | 609 Washington Hwy, Morrisville, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376500058 | NPI | - | NPPES |
| 080103401 | Other | VT | RR MEDICARE |
| 0004692 | Medicaid | VT | |
| 8000718 | Other | VT | LADIES FIRST |
| 00004692 | Other | VT | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 042-0005100 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Copley Hospital | Morrisville, VT | Hospital |
| The Manor, Inc | Morrisville, VT | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lamoille Health Partners Inc | 4789586942 | 37 |
News Archive
R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company - a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
Healthy living and pharmacy Expert and Commentator Marc Isaacson, CEO of Village Green Apothecary, the leading integrative pharmacy in the United States, announced today the release of their white paper, which provides a statistical analysis that explains why healthy living and prevention should be included, if not the focus of Healthcare Reform.
› Verified 5 days ago
| Entity Name | Lamoille Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124436332 PECOS PAC ID: 4789586942 Enrollment ID: O20040216000714 |
News Archive
R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company - a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
Healthy living and pharmacy Expert and Commentator Marc Isaacson, CEO of Village Green Apothecary, the leading integrative pharmacy in the United States, announced today the release of their white paper, which provides a statistical analysis that explains why healthy living and prevention should be included, if not the focus of Healthcare Reform.
› Verified 5 days ago
| Entity Name | Copley Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922029784 PECOS PAC ID: 9234125766 Enrollment ID: O20040811001413 |
News Archive
R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company - a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
Healthy living and pharmacy Expert and Commentator Marc Isaacson, CEO of Village Green Apothecary, the leading integrative pharmacy in the United States, announced today the release of their white paper, which provides a statistical analysis that explains why healthy living and prevention should be included, if not the focus of Healthcare Reform.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David M Coddaire, MD 607 Washington Hwy, Morrisville, VT 05661-8652 Ph: (802) 888-5639 | Dr David M Coddaire, MD 609 Washington Hwy, Morrisville, VT 05661-8652 Ph: (802) 888-5639 |
News Archive
R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company - a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
Healthy living and pharmacy Expert and Commentator Marc Isaacson, CEO of Village Green Apothecary, the leading integrative pharmacy in the United States, announced today the release of their white paper, which provides a statistical analysis that explains why healthy living and prevention should be included, if not the focus of Healthcare Reform.
› Verified 5 days ago
Dana Elizabeth Kennedy, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 609 Washington Hwy, Morrisville, VT 05661 Phone: 802-888-5639 Fax: 802-888-6040 | |
David Roy, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 609 Washington Hwy, Morrisville, VT 05661 Phone: 802-888-5688 Fax: 802-888-6040 | |
Mara V Vijups, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 609 Washington Hwy, Morrisville, VT 05661 Phone: 802-888-5639 Fax: 802-888-6040 | |
Dr. Jerry M Linseisen, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 528 Washington Hwy, Morrisville, VT 05661 Phone: 802-888-4231 Fax: 802-888-8203 | |
Dr. Tusa C Van Vogelpoel, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 609 Washington Hwy, Morrisville, VT 05661 Phone: 802-888-5639 Fax: 802-888-6040 | |
Dr. Gary Waring, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 530 Washington Hwy, Morrisville, VT 05661 Phone: 802-888-3096 |